Keeping Pace in Women’s Cancer: Targeting Advanced Endometrial Cancer - a podcast by ReachMD

CME credits: 0.25

Valid until: 06-05-2022

Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-womens-cancer-targeting-advanced-endometrial-cancer/12479/

Therapeutic options are changing for many patients with advanced endometrial cancer. Join us as Dr. Richard Penson and Dr. Nicoletta Colombo discuss new immunotherapeutic approaches and the importance of a patient’s tumor genomic profile when determining which interventional strategy, they receive. Also hear from Ms. Christine Ghione, a patient advocate, who provides a firsthand perspective of shared decision-making and how the process may be improved.

Since the production of this activity, the FDA has approved the use of dostarlimab for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Visit the FDA statement dated 22 April 2021 to learn more.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD